Nadai M, Bally J, Vitel M, Job C, Tissot G, Botterman J, Dubald M
Bayer BioScience, 14-20 Rue Pierre Baizet, BP 9163, 69263, Lyon cedex 09, France.
Transgenic Res. 2009 Apr;18(2):173-83. doi: 10.1007/s11248-008-9209-0. Epub 2008 Aug 7.
We have produced human alpha1-antitrypsin (A1AT), a major therapeutic protein, in genetically engineered tobacco plastids. Four different expression vectors have been evaluated which encode A1AT under the control of various 5' and 3' plastid expression elements. The use of heterologous promoter and terminator sequences derived from the corn and soybean plastid genomes leads to simpler and predictable recombinant genome patterns, avoiding unwanted recombination products between introduced and resident tobacco sequences. High level expression of unglycosylated A1AT, representing up to 2% of total soluble proteins, has been measured in leaves of transgenic tobacco lines. Some heterogeneity in the recombinant A1AT is detected after 2D protein separation, but the chloroplast-made protease inhibitors are fully active and bind to porcine pancreatic elastase.
我们已在基因工程烟草质体中生产出主要治疗性蛋白——人α1-抗胰蛋白酶(A1AT)。已评估了四种不同的表达载体,它们在各种5'和3'质体表达元件的控制下编码A1AT。使用源自玉米和大豆质体基因组的异源启动子和终止子序列可产生更简单且可预测的重组基因组模式,避免引入的烟草序列与常驻烟草序列之间产生不需要的重组产物。在转基因烟草品系的叶片中已检测到未糖基化A1AT的高水平表达,其含量高达总可溶性蛋白的2%。二维蛋白质分离后,在重组A1AT中检测到一些异质性,但叶绿体产生的蛋白酶抑制剂具有完全活性,并能与猪胰弹性蛋白酶结合。